Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25135837,slope parameter,The typical (95% confidence interval) slope parameter was estimated to be 0.941 (0.62-1.25) ms/ng/mL.,Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135837/),[ms] / [ml·ng],0.941,16369,DB01018,Guanfacine
,23832392,matrix effects,The matrix effects ranged from 89.4 to 100.7% and extraction recoveries were >90%.,"Development and validation of a simple, sensitive and accurate LC-MS/MS method for the determination of guanfacine, a selective α2A -adrenergicreceptor agonist, in plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23832392/),%,89.4 to 100.7,45142,DB01018,Guanfacine
>,23832392,extraction recoveries,The matrix effects ranged from 89.4 to 100.7% and extraction recoveries were >90%.,"Development and validation of a simple, sensitive and accurate LC-MS/MS method for the determination of guanfacine, a selective α2A -adrenergicreceptor agonist, in plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23832392/),%,90,45143,DB01018,Guanfacine
,3323255,absolute bioavailability,The absolute bioavailability of guanfacine after a single oral dose was 81.1%.,The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),%,81.1,57578,DB01018,Guanfacine
,3323255,elimination half-lives,"The elimination half-lives were 13.8 hours and 13.4 hours after oral and intravenous administration, respectively.",The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),h,13.8,57579,DB01018,Guanfacine
,3323255,elimination half-lives,"The elimination half-lives were 13.8 hours and 13.4 hours after oral and intravenous administration, respectively.",The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),h,13.4,57580,DB01018,Guanfacine
,3323255,volume of distribution,The volume of distribution results were approximately 6 L/kg by both routes of administration.,The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),[l] / [kg],6,57581,DB01018,Guanfacine
,3323255,plasma protein binding,"The mean plasma protein binding results were 71.6%, not influenced by plasma concentration or route of administration.",The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),%,71.6,57582,DB01018,Guanfacine
,3323255,urinary recovery,The urinary recovery of guanfacine was 44.3% after oral dosing and 50% after intravenous dosing.,The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),%,44.3,57583,DB01018,Guanfacine
,3323255,urinary recovery,The urinary recovery of guanfacine was 44.3% after oral dosing and 50% after intravenous dosing.,The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323255/),%,50,57584,DB01018,Guanfacine
,6762301,elimination rate constant,"After intravenous administration the elimination rate constant of the unchanged drug was calculated to be 0.59 h-1, corresponding to an elimination half-life of about 12 h, which is similar to the values of patients with normal renal function.",Pharmacokinetics of guanfacine in patients undergoing haemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6762301/),1/[h],0.59,138376,DB01018,Guanfacine
,6762301,elimination half-life,"After intravenous administration the elimination rate constant of the unchanged drug was calculated to be 0.59 h-1, corresponding to an elimination half-life of about 12 h, which is similar to the values of patients with normal renal function.",Pharmacokinetics of guanfacine in patients undergoing haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6762301/),h,12,138377,DB01018,Guanfacine
,6762301,clearance by dial,"The clearance by dialysis was 53 ml/min for guanfacine, which represents about 15% of the total clearance of guanfacine reported in the literature.",Pharmacokinetics of guanfacine in patients undergoing haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6762301/),[ml] / [min],53,138378,DB01018,Guanfacine
,3513525,absolute bioavailability,"In normal subjects, guanfacine was found to be rapidly and completely absorbed, with an absolute bioavailability close to 100% and therefore no evidence of a noticeable first-pass effect.",Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513525/),%,100,145239,DB01018,Guanfacine
,3513525,elimination half-life of the beta phase,"Its kinetics were best described by a 2-compartment model, with an elimination half-life of the beta phase of 17 hours.",Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513525/),h,17,145240,DB01018,Guanfacine
,3513525,urinary excretion,"The major route of excretion was in the urine, with urinary excretion of 80% of a given dose within 4 days.",Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513525/),%,80,145241,DB01018,Guanfacine
,17723079,AUC(0-infinity),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[h·ng] / [ml],65.2,173870,DB01018,Guanfacine
,17723079,AUC(0-infinity),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[h·ng] / [ml],47.3,173871,DB01018,Guanfacine
,17723079,C(max),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),ml·ng,2.55,173872,DB01018,Guanfacine
,17723079,C(max),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[ng] / [ml],1.69,173873,DB01018,Guanfacine
,17723079,AUC(0-24),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[h·ng] / [ml],70.0,173874,DB01018,Guanfacine
,17723079,AUC(0-24),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[h·ng] / [ml],48.2,173875,DB01018,Guanfacine
,17723079,C(max),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[ng] / [ml],4.39,173876,DB01018,Guanfacine
,17723079,C(max),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[ng] / [ml],2.86,173877,DB01018,Guanfacine
,17723079,AUC(0-24),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),[h·ng] / [ml],162,173878,DB01018,Guanfacine
,17723079,AUC(0-24),"Mean plasma concentrations, peak exposure (C(max)), and total or 24-hour exposure (area under the concentration-time curve [AUC](0-infinity) or AUC(0-24), respectively) were as follows in children and adolescents, respectively: after a single 2-mg dose, AUC(0-infinity) was 65.2 +/- 23.9 ng x hour/ml and 47.3 +/- 13.7 ng x hour/ml and C(max) was 2.55 +/- 1.03 ng x ml and 1.69 +/- 0.43 ng/ml after multiple 2-mg doses, AUC(0-24) was 70.0 +/- 28.3 ng x hour/ml and 48.2 +/- 16.1 ng x hour/ml and C(max) was 4.39 +/- 1.66 ng/ml and 2.86 +/- 0.77 ng/ml; and after multiple 4-mg doses, AUC(0-24) was 162 +/- 116 ng x hour/ml and 117 +/- 28.4 ng x hour/ml and C(max) was 10.1 +/- 7.09 ng/ml and 7.01 +/- 1.53 ng/ml.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),,117,173879,DB01018,Guanfacine
,17723079,half-life,"After a single 2-mg dose, half-life was 14.4 +/- 2.39 hours in children and 17.9 +/- 5.77 hours in adolescents.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),h,14.4,173880,DB01018,Guanfacine
,17723079,half-life,"After a single 2-mg dose, half-life was 14.4 +/- 2.39 hours in children and 17.9 +/- 5.77 hours in adolescents.",Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723079/),h,17.9,173881,DB01018,Guanfacine
,6994776,Total body clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],360,178295,DB01018,Guanfacine
,6994776,Total body clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],233,178296,DB01018,Guanfacine
,6994776,Total body clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],308,178297,DB01018,Guanfacine
,6994776,Total body clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],257,178298,DB01018,Guanfacine
,6994776,renal clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],233,178299,DB01018,Guanfacine
,6994776,renal clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],34,178300,DB01018,Guanfacine
,6994776,renal clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],257,178301,DB01018,Guanfacine
,6994776,renal clearance,"Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 +/- 262 (mean +/- s.d.) and 233 +/- 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 +/- 274 and 34 +/- 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 +/- 187 and 18 +/- 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).",Elimination of guanfacine in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),[ml] / [min],18,178302,DB01018,Guanfacine
,6994776,cumulative urinary excretion,"2. The cumulative urinary excretion up to 48 h after a single intravenous injection of guanfacine was 57.0 +/- 32.0% in patients with GFR > 90 ml/min, 14.0 +/- 9.0% in patients with GFR 30-10 ml/min and 7.5 +/- 2.4% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,57.0,178303,DB01018,Guanfacine
,6994776,cumulative urinary excretion,"2. The cumulative urinary excretion up to 48 h after a single intravenous injection of guanfacine was 57.0 +/- 32.0% in patients with GFR > 90 ml/min, 14.0 +/- 9.0% in patients with GFR 30-10 ml/min and 7.5 +/- 2.4% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,14.0,178304,DB01018,Guanfacine
,6994776,cumulative urinary excretion,"2. The cumulative urinary excretion up to 48 h after a single intravenous injection of guanfacine was 57.0 +/- 32.0% in patients with GFR > 90 ml/min, 14.0 +/- 9.0% in patients with GFR 30-10 ml/min and 7.5 +/- 2.4% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,7.5,178305,DB01018,Guanfacine
,6994776,elimination rate constant,"3. In normal as well as impaired renal function the elimination rate constant of guanfacine was 0.05 h-1, which corresponds to an elimination half-life of 14 h, independent of renal function.",Elimination of guanfacine in patients with normal and impaired renal function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),1/[h],0.05,178306,DB01018,Guanfacine
,6994776,elimination half-life,"3. In normal as well as impaired renal function the elimination rate constant of guanfacine was 0.05 h-1, which corresponds to an elimination half-life of 14 h, independent of renal function.",Elimination of guanfacine in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),h,14,178307,DB01018,Guanfacine
,6994776,Intestinal absorption,"5. Intestinal absorption of guanfacine was calculated to be 59 +/- 19% in patients with GFR > 90 ml/min, to 68 +/- 16% in patients with GFR 30-10 ml/min, and to 73 +/- 36% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,59,178308,DB01018,Guanfacine
,6994776,Intestinal absorption,"5. Intestinal absorption of guanfacine was calculated to be 59 +/- 19% in patients with GFR > 90 ml/min, to 68 +/- 16% in patients with GFR 30-10 ml/min, and to 73 +/- 36% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,68,178309,DB01018,Guanfacine
,6994776,Intestinal absorption,"5. Intestinal absorption of guanfacine was calculated to be 59 +/- 19% in patients with GFR > 90 ml/min, to 68 +/- 16% in patients with GFR 30-10 ml/min, and to 73 +/- 36% in preuremic patients.",Elimination of guanfacine in patients with normal and impaired renal function. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994776/),%,73,178310,DB01018,Guanfacine
,761440,lag time,"After a lag time of 0.8 hr, the absorption occurred rapidly (t 1/2 congruent to 0.53 hr).",Guanfacine kinetics in patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761440/),h,0.8,204656,DB01018,Guanfacine
,761440,t 1/2,"After a lag time of 0.8 hr, the absorption occurred rapidly (t 1/2 congruent to 0.53 hr).",Guanfacine kinetics in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761440/),h,0.53,204657,DB01018,Guanfacine
,761440,t 1/2s,The fast and slow elimination phases occurred with t 1/2s of 2 and 19 hr.,Guanfacine kinetics in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761440/),h,2,204658,DB01018,Guanfacine
,761440,t 1/2s,The fast and slow elimination phases occurred with t 1/2s of 2 and 19 hr.,Guanfacine kinetics in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761440/),h,19,204659,DB01018,Guanfacine
,7029332,peak plasma levels,"GF was rapidly absorbed, the peak plasma levels (13.28 +/- 1.58 ng/ml) being reached within two hours.",[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),[ng] / [ml],13.28,234207,DB01018,Guanfacine
,7029332,t 1/2 of the beta phase,"The plasma level decreased with a bi-exponential pattern, with a t 1/2 of the beta phase of 24.4 +/- 3.2 h.",[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),h,24.4,234208,DB01018,Guanfacine
,7029332,plasma clearance,The plasma clearance was 212 +/- 40 ml/min and the renal clearance 13.9 +/- 5.2 ml/min.,[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),[ml] / [min],212,234209,DB01018,Guanfacine
,7029332,renal clearance,The plasma clearance was 212 +/- 40 ml/min and the renal clearance 13.9 +/- 5.2 ml/min.,[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),[ml] / [min],13.9,234210,DB01018,Guanfacine
,7029332,elimination (t 1/2 beta,The comparison of these results with those observed in hypertensive patients with a normal renal function demonstrates a slower elimination (t 1/2 beta in the reference group of 16.7 h) and a decrease of the total and renal clearances (445 +/- 29 ml/min and 144 +/- 6 ml/min respectively of the reference group) which directly correlated with the decrease of the CCr.,[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),h,16.7,234211,DB01018,Guanfacine
,7029332,total,The comparison of these results with those observed in hypertensive patients with a normal renal function demonstrates a slower elimination (t 1/2 beta in the reference group of 16.7 h) and a decrease of the total and renal clearances (445 +/- 29 ml/min and 144 +/- 6 ml/min respectively of the reference group) which directly correlated with the decrease of the CCr.,[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),[ml] / [min],445,234212,DB01018,Guanfacine
,7029332,renal clearances,The comparison of these results with those observed in hypertensive patients with a normal renal function demonstrates a slower elimination (t 1/2 beta in the reference group of 16.7 h) and a decrease of the total and renal clearances (445 +/- 29 ml/min and 144 +/- 6 ml/min respectively of the reference group) which directly correlated with the decrease of the CCr.,[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029332/),[ml] / [min],144,234213,DB01018,Guanfacine
,25724291,apparent clearance (CL/F),"Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33.1 (30.2-36.4) L/h for apparent clearance (CL/F), 804 (703-900) L for apparent volume of distribution, 0.552 (0.437-0.670) h(-1) for the absorption rate constant, and 0.651 (0.608-0.697) h for absorption lag time.",Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724291/),[l] / [h],33.1,247482,DB01018,Guanfacine
,25724291,apparent volume of distribution,"Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33.1 (30.2-36.4) L/h for apparent clearance (CL/F), 804 (703-900) L for apparent volume of distribution, 0.552 (0.437-0.670) h(-1) for the absorption rate constant, and 0.651 (0.608-0.697) h for absorption lag time.",Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724291/),l,804,247483,DB01018,Guanfacine
,25724291,absorption rate constant,"Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33.1 (30.2-36.4) L/h for apparent clearance (CL/F), 804 (703-900) L for apparent volume of distribution, 0.552 (0.437-0.670) h(-1) for the absorption rate constant, and 0.651 (0.608-0.697) h for absorption lag time.",Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724291/),1/[h],0.552,247484,DB01018,Guanfacine
,25724291,absorption lag time,"Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33.1 (30.2-36.4) L/h for apparent clearance (CL/F), 804 (703-900) L for apparent volume of distribution, 0.552 (0.437-0.670) h(-1) for the absorption rate constant, and 0.651 (0.608-0.697) h for absorption lag time.",Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724291/),h,0.651,247485,DB01018,Guanfacine
,25115365,apparent Km,"The apparent Km and Vmax values of guanfacine uptake by hOCT2 were 96.19 ± 7.49 μM and 13.03 ± 0.49 nmol/mg protein/min, respectively.","Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),μM,96.19,259892,DB01018,Guanfacine
,25115365,Vmax,"The apparent Km and Vmax values of guanfacine uptake by hOCT2 were 96.19 ± 7.49 μM and 13.03 ± 0.49 nmol/mg protein/min, respectively.","Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),[nM] / [·mg·min],13.03,259893,DB01018,Guanfacine
,25115365,IC50,Guanfacine transport mediated by hOCT2 was significantly inhibited by a typical OCT2 inhibitor cimetidine with an IC50 value of 93.82 ± 1.13 μM.,"Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),μM,93.82,259894,DB01018,Guanfacine
,17617285,C(max),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ng] / [ml],0.98,264919,DB01018,Guanfacine
,17617285,C(max),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ng] / [ml],1.57,264920,DB01018,Guanfacine
,17617285,C(max),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ng] / [ml],3.58,264921,DB01018,Guanfacine
,17617285,AUC(0-t),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],29.3,264922,DB01018,Guanfacine
,17617285,AUC(0-t),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],54.5,264923,DB01018,Guanfacine
,17617285,AUC(0-t),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],119.1,264924,DB01018,Guanfacine
,17617285,AUC(0-infinity),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],32.4,264925,DB01018,Guanfacine
,17617285,AUC(0-infinity),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],58.0,264926,DB01018,Guanfacine
,17617285,AUC(0-infinity),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),[ml·ng] / [h],124.1,264927,DB01018,Guanfacine
,17617285,t((1/2)),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),h,17.5,264928,DB01018,Guanfacine
,17617285,t((1/2)),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),h,16.6,264929,DB01018,Guanfacine
,17617285,t((1/2)),"Mean (SD) values for guanfacine plasma concentrations with GXR 1, 2, and 4 mg, respectively, were 0.98 (0.26), 1.57 (0.51), and 3.58 (1.39) ng/mL for C(max); 29.3 (8.84), 54.5 (17.7), and 119.1 (42.3) ng/mL . h(-1) for AUC(0-t); and 32.4 (8.78), 58.0 (18.9), and 124.1 (45.1) ng/mL . h(-1) for AUC(0-infinity) . Mean (SD) t((1/2)) values were 17.5 (3.8), 16.6 (3.8), and 16.7 (4.90) hours for GXR 1, 2, and 4 mg, respectively.","A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617285/),h,16.7,264930,DB01018,Guanfacine
,29403858,flow rate,"Mobile phase used was 10 mM ammonium formate (pH 4.0):acetonitrile (70:30, v/v) at a flow rate of 0.3 mL/min.",Method development and validation of Guanfacine in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403858/),[ml] / [min],0.3,266309,DB01018,Guanfacine
